Volume 26, Issue 6 (May 2016)
Japanese

Parathyroid Hormone. Bone disease in the field of CKD-MBD. Yajima Aiji 1 , Tsuchiya Ken 2 , Yokota Hiroki 3 , Nitta Kosaku 2 1Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis /Department of Anatomy and Cell Biology, Indiana University, School of Medicine, USA./Department of Medicine, Kidney Center, Tokyo Women's Medical University, Japan. 2Department of Medicine, Kidney Center, Tokyo Women's Medical University, Japan. 3Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis/Department of Anatomy and Cell Biology, Indiana University, School of Medicine, USA. pp.875-880
Published Date 2016/5/28
DOI https://doi.org/10.20837/4201606069
  • Abstract
  • Look Inside
  • Reference

 The pathophysiology and treatment for renal bone disease have made remakable progress. Moreover, osteocyte reseach has made tremendous progress. In the clinical aspect,(1)hyperphosphatemia,(2)hyperparathyroid and hypoparathyroid bone disease in patients with chronic kidney disease,(3)increased serum level of fibroblast growth factor 23(FGF-23) and(4)reduced level of Klotho should be taken into consideration when analyzing these conditions. On the other hand, hyperphosphatemia must be successfully treated. Hyperparathyroid bone disease has been successfully treated with vitamin D sterol, cinacalcet hydrochloride and parathyroidectomy, however, the treatment of hypoparathyroidism inpatient with diabetes or non-diabetes met with high hurdles. We must treat these patients in thinking about osteocytic perilacunar/canalicular system.



基本情報

09175857.26.6.jpg
CLINICAL CALCIUM
26巻6号 (2016年5月)
電子版ISSN 印刷版ISSN 0917-5857 医薬ジャーナル社

関連文献

もっと見る

文献を共有